Schering-Plough Ltd, Singapore Branch was the first US pharmaceutical company to establish manufacturing operations in Singapore. With investments exceeding US$1 billion and 7 manufacturing plants producing active drug substances, tablets, dry powder inhalers, sterile injectables and nasal sprays; we are among the largest pharmaceutical investors in Singapore. Our Asia regional office for manufacturing is also in Singapore. (Click here to view site)

SOL Ltd is the Singapore operation comprising Sales & Marketing, Regional Office and Distribution Centre, Finance Shared Services Asia Pacific as well as the Regional Clinical Trial and Research organization.

Schering-Plough Technologies Pte Ltd launched the Translational Medicine Research Centre (TMRC) in Feburary 2009 which is part of the Schering-Plough Research Institute (SPRI). The centre focuses on translating the vast progress in fundamental biomedical research into benefits for patients and comprises a Translational Research Laboratory (TRL) as well as a Translational Medicine Unit (TMU).